CDTX.Cidara Therapeutics, INC

Form 4: Cidara Therapeutics COO & CLO, Shane Ward, Reports Acquisition of Stock and Stock Options

Sentiment:

SEC Form 4 Filing

📋All filings for Cidara Therapeutics, INC
🔒Login to Follow

Shane Ward, COO & CLO of Cidara Therapeutics, reports acquiring 120,000 shares of common stock and 250,000 employee stock options on March 15, 2024.

Summary

  • On March 15, 2024, Shane Ward, the COO & CLO of Cidara Therapeutics, acquired 120,000 shares of common stock.
  • These shares were acquired through time-based Restricted Stock Units (RSUs).
  • Ward also acquired 250,000 employee stock options with an exercise price of $0.6849.
  • The stock options vest in 36 equal monthly installments starting from March 15, 2024.
  • The RSUs vest in three equal annual installments starting March 10, 2025.
  • Following these transactions, Ward beneficially owns 318,770 shares of common stock and 250,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating insider transactions. The acquisition of shares and options by an executive could be interpreted as a positive sign, but it's not definitively bullish.

Positives

  • The acquisition of stock and stock options by a high-ranking officer may signal confidence in the company's future prospects.

Future Outlook

The vesting schedules for both the RSUs and stock options indicate a long-term commitment from the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies. This filing indicates changes in beneficial ownership by a company insider.

Stakeholder Impact

  • The reported transactions may have a minor positive impact on shareholder sentiment.

Key Dates

DateDescription
03/15/2024Date of transaction: Acquisition of common stock and stock options.
03/15/2024Vesting Commencement Date for stock options.
03/10/2025First vesting date for 1/3 of the RSUs.
03/10/2026Second vesting date for 1/3 of the RSUs.
03/10/2027Final vesting date for 1/3 of the RSUs.
03/14/2034Expiration date of the employee stock options.
03/20/2024Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.